JPS6410520B2 - - Google Patents
Info
- Publication number
- JPS6410520B2 JPS6410520B2 JP54026696A JP2669679A JPS6410520B2 JP S6410520 B2 JPS6410520 B2 JP S6410520B2 JP 54026696 A JP54026696 A JP 54026696A JP 2669679 A JP2669679 A JP 2669679A JP S6410520 B2 JPS6410520 B2 JP S6410520B2
- Authority
- JP
- Japan
- Prior art keywords
- protease inhibitor
- manufactured
- solution
- constant
- minutes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 26
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 25
- 108090000631 Trypsin Proteins 0.000 claims description 10
- 102000004142 Trypsin Human genes 0.000 claims description 10
- 239000012588 trypsin Substances 0.000 claims description 10
- 238000009792 diffusion process Methods 0.000 claims description 7
- 238000001962 electrophoresis Methods 0.000 claims description 7
- 238000004062 sedimentation Methods 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 4
- 238000000921 elemental analysis Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 238000000034 method Methods 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 235000010469 Glycine max Nutrition 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 244000068988 Glycine max Species 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 239000008363 phosphate buffer Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 229920005654 Sephadex Polymers 0.000 description 5
- 239000012507 Sephadex™ Substances 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 235000019419 proteases Nutrition 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000004252 protein component Nutrition 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- 108091005658 Basic proteases Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000005158 Subtilisins Human genes 0.000 description 2
- 108010056079 Subtilisins Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 108091005508 Acid proteases Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101100293591 Mus musculus Art1 gene Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明はトリプシンのみを特異的に阻害する新
規な蛋白質分解酵素阻害物質−に関する。
本発明者らは大豆貯蔵蛋白質のうち比較的小さ
な分子量分布を持つ2S沈降成分(2Sグロブリン
区分)の成分組成を詳細に検討していたところ、
トリプシンのみに阻害活性を有する蛋白質分解酵
素阻害物質が存在することを見出し、種々検討し
た結果これを単離することに成功した。
すなわち本発明は、下記の理化学的性質を有す
る蛋白質分解酵素阻害物質−。
作用:トリプシンのみを阻害する。
至適PH及び安定PH範囲:いずれもPH3〜10で
ある。
作用適温の範囲:70℃以下。
分子量:28500。
等電点:PH4.65。
電気泳動:電気泳動的に均一である。
沈降定数及び拡散定数:沈降定数は2.68Sで
あり、拡散定数は9.21×10-7cm2/secである。
元素分析:C;42.35%、H;6.85%、N;
12.26%。
アミノ酸分析値:第2表の通り。
である。
以下、本発明を詳細に説明する。
先ず、本発明の精製された蛋白質分解酵素阻害
物質−(以下、プロテアーゼ・インヒビター・
と略称する)の理化学的性質について記載す
る。
(1) 作用
本プロテアーゼ・インヒビター・は、第1
表に示す如くトリプシンのみを阻害する作用を
有する。
The present invention relates to a novel proteinase inhibitor that specifically inhibits only trypsin. The present inventors investigated in detail the composition of the 2S precipitated component (2S globulin category), which has a relatively small molecular weight distribution among soybean storage proteins, and discovered that
We discovered that there is a protease inhibitor that has inhibitory activity only against trypsin, and after various studies, we succeeded in isolating it. That is, the present invention provides a protease inhibitor having the following physical and chemical properties. Action: Inhibits trypsin only. Optimal PH and stable PH range: Both are PH3-10. Suitable temperature range for action: 70℃ or less. Molecular weight: 28500. Isoelectric point: PH4.65. Electrophoresis: Electrophoretically homogeneous. Sedimentation constant and diffusion constant: Sedimentation constant is 2.68S and diffusion constant is 9.21×10 −7 cm 2 /sec. Elemental analysis: C; 42.35%, H; 6.85%, N;
12.26%. Amino acid analysis value: As shown in Table 2. It is. The present invention will be explained in detail below. First, the purified protease inhibitor of the present invention (hereinafter referred to as protease inhibitor)
The physical and chemical properties of (abbreviated as) are described below. (1) Action This protease inhibitor is the first protease inhibitor.
As shown in the table, it has the effect of inhibiting only trypsin.
【表】
上表中、(※1)アルカリ・プロテアーゼ
(Asp.soyae)は、K.Hayashi、D.Fukushima
& K.Mogi、Agr.Biol.Chem.31 1237
(1967)、(※2)酸性プロテアーゼ(Asp.
soyae)は特開昭50−121486号(微工研菌寄第
505号)及び(※3)酸性プロテアーゼ(Asp.
saitoi)はE.Ichishima & F.Yoshida、
Biochim.Biophys.Acta.99 360(1965)に、
夫々記載される酵素である。
第1表中、酵素阻害活性度の測定は以下の方
法により測定した。
(イ) トリプシン、キモトリプシン、ズブチリシ
ンA、ズブチリシンBPN′、プロテアーゼ、
サーモリシン及び(※1)アルカリ・プロテ
アーゼに対する阻害活性度の測定は、クニツ
ツ(Kunits)のカゼイン消化法により測定
した。
試料(プロテアーゼ・インヒビター・)
0.5mlを試験管に取り、これを37℃の恒温槽
に2分間保持したのち、これに予め37℃に保
温した酵素溶液〔上記酵素を、酢酸カルシウ
ム2mMを含む1/20Mトリス−塩酸緩衝液
(PH8.0)0.5mlに30μg含むように夫々調製し
た溶液〕0.5mlを試験管に加え2分間37℃で
保持し、次いで37℃に保温したカゼインン溶
液〔カゼイン(メルク社製)1gを、酢酸カ
ルシウム2mMを含む1/20Mトリス−塩酸緩
衝液(PH8.0)100mlに溶解した液〕1mlを加
え、正確に37℃で20分間反応させた。
次いでこれに5%トリクロル酢酸3mlを加
えて反応を止め、1時間放置後東洋濾紙No.
5Cで濾過し、濾紙の吸光度を280nmの吸収
波長で測定した。
(ロ) ペプシン、(※2)酸性プロテアーゼ、(※
3)酸性プロテアーゼ及び酸性プロテアーゼ
(生化学工業社製)に対する阻害活性度の測
定法は、以下の通りである。
試料(プロテアーゼ・インヒビター・)
0.5mlを試験管に取り、これを37℃の恒温槽
に2分間保持したのち、これに予め37℃に保
温した酵素溶液〔上記酵素を、0.1M酢酸ソ
ーダー塩酸緩衝液(PH2.7)0.5mlに30μg含
むように夫々調製した溶液〕0.5mlを試験管
に加え2分間37℃で保持し、次いで37℃に保
温したカゼイン溶液〔カゼイン(メルク社
製)2gを、1N塩酸でPH2.7になるように調
整しつつ懸濁し、水を加えて100mlとした溶
液〕1mlを加え、正確に37℃で20分間反応さ
せたのち、これに5%トリクロル酢酸3mlを
加えて反応を止め、1時間放置後東洋濾紙No.
5Cで濾過し、濾紙の吸光度を280nmの吸収
波長で測定した。
(ハ) プラスミンに対する阻害活性度の測定はロ
ビンズらの方法〔K.C.Robbins & L.
Summaria、Methods in Enzymology 19
184(1970)〕により測定した。
試料(プロテアーゼ・インヒビター・)
0.5mlと0.067M燐酸緩衝液(PH7.4)1mlとを
試験管に取り、これを37℃の恒温槽に2分間
保持したのち、これに予め37℃に保温した酵
素溶液〔上記酵素を、0.05M・トリスアミノ
メタン、0.02M・L−リジン、0.1M・塩化
化ナトリウム及び0.001M・EDTAを加え、
苛性ソーダでPH9に調整した緩衝液0.5mlに
30μg含むように夫々調製した溶液〕0.5mlを
試験管に加え2分間37℃に保持し、次いで37
℃に保温したカゼイン溶液〔カゼイン(メル
ク社製)4gを、0.067M燐酸緩衝液(PH
7.4)100mlに溶解した溶液〕1mlを加え、正
確に37℃で20分間反応させた。次いでこれに
15%トリクロル酢酸3mlを加えて反応を止
め、1時間放置後東洋濾紙No.5Cで濾過し、
濾紙の吸光度を280nmの吸収波長で測定し
た。
なお第1表の酵素阻害活性度は、1μgの
本プロテアーゼ・インヒビター・により阻
害される酵素のμgとして求めた。
(2) 至適PH及び安定PH範囲
第1図の如く、本プロテアーゼ・インヒビタ
ー・のトリプシンに対する阻害活性の安定PH
及び至適PHの範囲はPH3〜10である。
(3) 作用適温の範囲
第2図に示すように、本プロテアーゼ・イン
ヒビター・のトリプシンに対する阻害活性の
作用適温の範囲は、70℃以下である。
(4) PH、温度などによる失活条件
PHに対しては、第1図より明らかな如く酸性
側のPHでは約30%失活し、アルカリ性側のPH12
で10%失活し、又PH13以上では著しく失活す
る。
又熱に対しては、第2図より100℃、20分間
で約30%失活し、又110℃、20分間でほぼ完全
に失活する。
(5) 精製方法
PH5.4〜5.8で抽出された大豆蛋白質をPH4.5で
等電点沈殿させて得られる沈殿区分を、0.01M
燐酸緩衝液(PH7.60)に溶解するか、又は該溶
解液を透析膜に入れ上記緩衝液(PH7.60)で透
析し、該透析内液をダイヤフロー膜(米国、ア
ミコン社製)、コロジオン膜(西独、ザルトリ
ウス・メンブランフイルター社製)等で濃縮す
る。
次に上記溶解液もしくは濃縮液をセフアデツ
クスG−100(スウエーデン、フアーマシヤ社
製)、バイオゲルP−100(米国、バイオラド社
製)等のカラムを用いてゲル濾過し、7S沈降
蛋白質を除去して2S沈降成分のみを集める。
次いで2S沈降成分をDEAE−セフアデツクス
(スウエーデン、フアーマシヤ社製)、DEAE−
セルロース(米国、ブラウン社製)等のカラム
に吸着させたのち、塩化ナトリウムによる濃度
勾配溶出を行ない、0.23〜0.30M(モル)の塩
化ナトリウム濃度で溶出する区分を集め、本発
明のプロテアーゼ・インヒビター・を得る。
(6) 分子量
本プロテアーゼ・インヒビター・の分子量
はヨハンテイス法〔D.A.Yphantis、Ann.N.Y.
Acad.Sci.88 586(1960)〕により測定した結
果、28、500であつた。
(7) 等電点
焦点電気泳動装置(スウエーデン、LKB.社
製)及びアンフオライン(PH3〜10)を用いて
測定した結果、プロテアーゼ・インヒビター・
はPH4.65であつた。
(8) 電気泳動
デイスク電気泳動法〔L.Ornstein Ann.N.Y.
Acad.Sci.121Art2、321(1964)、B.J.Davis
Ann.N.Y.Acad.Sci.121Art2、404(1964)〕によ
り15%ポリアクリルアミドを用いて測定した結
果、第3図に示す如く電気泳動的に均一であつ
た。
(9) 沈降定数及び拡散定数
沈降定数の測定は、〔渡辺格、島内武彦、培
風館、生物化学実験法9頁(1962)〕の方法に
準じ、又拡散定数の測定は、〔K.Kawahara
Biochemistry8 2551(1969)〕の方法に準じ
て行なつた結果を以下に示す。
沈降定数(S゜20、W)は2.68Sであり、又拡
散定数(D20、W)は9.21×10-7cm2/secであつ
た。
(10) 元素分析
C;42.35%
H;6.85%
N;12.26%
(11) アミノ酸分析値(日立KLA−5型アミノ酸
分析計を用いて測定)
アミノ酸分析値の表示は、プロテアーゼ・イ
ンヒビター・100g当たりのアミノ酸のg数
で示した。[Table] In the above table, (*1) alkaline protease (Asp. soyae) is K. Hayashi, D. Fukushima.
& K.Mogi, Agr.Biol.Chem. 31 1237
(1967), (*2) Acid protease (Asp.
soyae) is published in Japanese Patent Application Laid-open No. 121486 (1983)
505) and (*3) acidic protease (Asp.
Saitoi) is E.Ichishima & F.Yoshida,
Biochim. Biophys. Acta. 99 360 (1965),
These are the enzymes described respectively. In Table 1, the enzyme inhibitory activity was measured by the following method. (a) Trypsin, chymotrypsin, subtilisin A, subtilisin BPN', protease,
The inhibitory activity against thermolysin and (*1) alkaline protease was measured using the Kunits casein digestion method. Sample (protease inhibitor)
Transfer 0.5 ml to a test tube, keep it in a constant temperature bath at 37°C for 2 minutes, and then add the enzyme solution previously kept at 37°C. (PH8.0) 0.5 ml of each solution was prepared so that 0.5 ml contained 30 μg] was added to a test tube and kept at 37°C for 2 minutes, and then kept at 37°C. 1 ml of a solution dissolved in 100 ml of 1/20M Tris-HCl buffer (PH8.0) containing 2 mM calcium acetate was added, and the mixture was allowed to react at exactly 37°C for 20 minutes. Next, 3 ml of 5% trichloroacetic acid was added to this to stop the reaction, and after standing for 1 hour, Toyo Roshi No.
It was filtered at 5C, and the absorbance of the filter paper was measured at an absorption wavelength of 280 nm. (b) Pepsin, (*2) acidic protease, (*
3) The method for measuring the inhibitory activity against acidic protease and acidic protease (manufactured by Seikagaku Corporation) is as follows. Sample (protease inhibitor)
Transfer 0.5 ml to a test tube and keep it in a constant temperature bath at 37℃ for 2 minutes. Add 0.5 ml of each solution to a test tube and hold at 37°C for 2 minutes, then keep at 37°C Casein solution [2 g of casein (Merck) was diluted with 1N hydrochloric acid to pH 2.7 Add 1 ml of the solution to 100 ml and add 1 ml of the solution to 100 ml. Add 1 ml of the solution and allow to react at exactly 37°C for 20 minutes. Add 3 ml of 5% trichloroacetic acid to stop the reaction. Toyo Roshi No. after standing for a while.
It was filtered at 5C, and the absorbance of the filter paper was measured at an absorption wavelength of 280 nm. (c) The inhibitory activity against plasmin was measured by the method of Robbins et al. [KCRobbins & L.
Summaria, Methods in Enzymology 19
184 (1970)]. Sample (protease inhibitor)
0.5 ml and 1 ml of 0.067M phosphate buffer (PH7.4) were placed in a test tube, and this was kept in a constant temperature bath at 37°C for 2 minutes. Add 0.05M trisaminomethane, 0.02M L-lysine, 0.1M sodium chloride and 0.001M EDTA,
Add to 0.5ml of buffer solution adjusted to pH9 with caustic soda.
Add 0.5 ml of each solution prepared to contain 30 μg to a test tube, hold at 37°C for 2 minutes, and then
A casein solution [4 g of casein (manufactured by Merck & Co., Ltd.) kept at ℃ was added to a 0.067M phosphate buffer (PH
7.4) Add 1 ml of solution dissolved in 100 ml and react at exactly 37°C for 20 minutes. Then this
The reaction was stopped by adding 3 ml of 15% trichloroacetic acid, and after being left for 1 hour, it was filtered through Toyo Roshi No. 5C.
The absorbance of the filter paper was measured at an absorption wavelength of 280 nm. The enzyme inhibition activity in Table 1 was determined as μg of enzyme inhibited by 1 μg of the present protease inhibitor. (2) Optimal PH and stable PH range As shown in Figure 1, stable PH for the inhibitory activity of this protease inhibitor against trypsin.
And the optimum pH range is PH3-10. (3) Range of optimum temperature for action As shown in Figure 2, the optimum temperature range for the inhibitory activity of this protease inhibitor against trypsin is 70°C or lower. (4) Deactivation conditions due to PH, temperature, etc. As shown in Figure 1, about 30% deactivation occurs at acidic PH, and about 30% deactivation occurs at alkaline PH of 12.
It loses its activity by 10% at pH 13 or higher, and it loses its activity significantly at pH 13 or above. Regarding heat, as shown in Figure 2, it is deactivated by about 30% at 100°C for 20 minutes, and almost completely deactivated at 110°C for 20 minutes. (5) Purification method The soybean protein extracted at PH5.4-5.8 is isoelectrically precipitated at PH4.5, and the precipitate fraction obtained is 0.01M.
Dissolve in phosphate buffer (PH7.60) or put the solution into a dialysis membrane and dialyze against the above buffer (PH7.60), and the dialyzed solution is transferred to a Diaflow membrane (manufactured by Amicon, USA), Concentrate with a collodion membrane (manufactured by Sartorius Membrane Filter, West Germany), etc. Next, the above solution or concentrate is gel-filtered using a column such as Sephadex G-100 (manufactured by Pharmacia, Sweden) or Biogel P-100 (manufactured by Bio-Rad, USA) to remove the 7S precipitated protein. Collect only the sedimented components.
Next, the 2S precipitated components were treated with DEAE-Sephadex (manufactured by Pharmacia, Sweden) and DEAE-
After adsorbing on a column such as cellulose (manufactured by Braun, USA), concentration gradient elution with sodium chloride is performed, and the fraction eluting at a sodium chloride concentration of 0.23 to 0.30 M (mol) is collected.・Obtain. (6) Molecular weight The molecular weight of this protease inhibitor was determined by the Johantheis method [DAYphantis, Ann.NY
Acad.Sci. 88 586 (1960)], it was 28,500. (7) Isoelectric point As a result of measurement using a focusing electrophoresis device (manufactured by LKB., Sweden) and Ampholine (PH3-10), protease inhibitor
The pH was 4.65. (8) Electrophoresis Disk electrophoresis method [L.Ornstein Ann.NY
Acad.Sci. 121 Art2, 321 (1964), BJDavis
Ann.NYAcad.Sci. 121 Art 2, 404 (1964)] using 15% polyacrylamide, it was found to be electrophoretically uniform as shown in FIG. (9) Sedimentation constant and diffusion constant The measurement of the sedimentation constant follows the method of [K. Watanabe, Takehiko Shimauchi, Baifukan, Biochemistry Experimental Methods, p. 9 (1962)], and the measurement of the diffusion constant follows the method of [K. Kawahara.
Biochemistry 8 2551 (1969)] The results are shown below. The sedimentation constant (S°20, W) was 2.68S, and the diffusion constant (D20, W) was 9.21×10 −7 cm 2 /sec. (10) Elemental analysis C; 42.35% H; 6.85% N; 12.26% (11) Amino acid analysis value (measured using Hitachi KLA-5 model amino acid analyzer) Amino acid analysis value is displayed per 100g of protease inhibitor. It is expressed in grams of amino acids.
【表】
前述の理化学的性質を有する本発明のプロテア
ーゼ・インヒビター・は、生化学試薬として、
又急性すい炎などの治療用医薬として、その用途
が広く期待される。
次に本発明のプロテアーゼ・インヒビター・
の製造法は具体的に述べる。
本発明に用いられる製造原料としては、日本産
のボンミノリ種、陽月1号種、野起白花種、米国
産のケント種等の大豆品種が用いられ、これらの
品種の大豆又はこれを常法により脱脂した脱脂大
豆をそのままか粉砕し、これらに対し10〜20倍量
の水もしくは塩化ナトリウム、塩化カリ等の塩類
溶液を加え、酢酸、塩酸、硫酸、燐酸等でPHを
5.4〜5.8に調整し、必要により撹拌しつつ蛋白質
を抽出する。その際大豆中の主要蛋白質成分の一
種である11S成分はPH5.4〜5.8で選択的に沈降す
るため、該11S成分を遠心分離により除去する。
次いで得られた上清成分を上述の酸を用いてPH
4.5として等電沈殿させ、次いで遠心分離により
上清の大豆ホエー区分を分離させる。得られた沈
殿蛋白質0を0.01M燐酸緩衝液(PH7.60)に溶解
するか、又は該溶解液を透析膜に入れ上記緩衝液
(PH7.60)で透析し、該透析内液をダイヤフロー
膜(米国、アミコン社製)、コロジオン膜(西独、
ザルトリウス・メンブランフイルター社製)等で
濃縮する。
次に上記溶解液もしくは濃縮液をセフアデツク
スG−100(スウエーデン、フアーマシヤ社製)、
バイオゲルP−100(米国、バイオラド社製)等の
カラムを用いてゲル濾過するか、又はXM50、
XY100A等のダイヤフロー限外濾過膜(米国、ア
ミコン社製)等を用いて限外濾過し、7S蛋白質
等の高分子蛋白質区分を除去して2S沈殿成分に
のみを集める。次いで2S沈降成分をDEAE−セ
フアデツクス(スウエーデン、フアーマシヤ社
製)、DEAE−セルロース(米国、ブラウン社製)
等の陰イオン交換体のカラムに吸着させたのち、
これを塩化ナトリウム、塩化カリウム等の塩の濃
度差による溶出を行なつて、分画処理し本プロテ
アーゼ・インヒビター・を得る。
なお、上記塩化ナトリウムを用いて塩濃度差に
より溶出を行なう場合、本プロテアーゼ・インヒ
ビター・は0.23〜0.30M(モル)の塩化ナトリ
ウム濃度範囲に於いて溶出される。
以下、実施例により本発明を具体的に説明す
る。
実施例 1
大豆(品種;野起白花)を粉砕し、38〜40℃、
エチルエーテルで抽出して得られる脱脂大豆ミー
ル100gに、1の水を加えPHを濃氷酢酸で5.8と
し1時間撹拌して蛋白質成分を抽出する。次いで
該抽出液を、ガーゼで濾過し抽出残渣を除去した
のち、抽出液を18000r.p.m.で1時間遠心分離し
680mlの上清液を得た。上清液を濃氷酢酸でPH4.5
とし、沈殿した蛋白質区分を3000r.p.m.で10分
間、遠心分離して集めた。得られた沈殿区分を直
ちに0.01M燐酸緩衝液(PH7.60)400mlに懸濁し、
更に該緩衝液(PH7.60)で一昼夜透析する。次い
で透析内液を30000r.p.m.で30分間遠心分離し、
不溶性蛋白質を取り除いたのち、これを5cm×90
cmのセフアデツクスG−100(スウエーデン、フア
ーマシヤ社製)のカラムに100mlずつ充填し、前
記緩衝液(PH7.60)でゲル濾過を行ない、フラク
シヨンコレクターで15mlずつ分取しNo.66〜76に於
いてて溶出する区分を集め、これを十分水に透析
後、凍結乾燥して320mgの標品を得た。次いで該
乾燥標品200mgを0.01M燐酸緩衝液(PH7.60)に
溶解し、これを1cm×20cmのDEAE−セフアデツ
クス(スウエーデン、フアーマシヤ社製)のカラ
ムに充填し、250mlの容器を用いて塩化ナトリウ
ムで0〜0.5Nまでの濃度勾配溶出を行ない、塩
化ナトリウム濃度0.23〜0.30Mに溶出する区分を
集め、これを水に透析後、凍結乾燥し、さらに上
記カラムで再クロマトグラフイーを行なつて、本
プロテアーゼ・インヒビター・の精製標品36.7
mgを得た。
実施例 2
大豆(品種;ボンミノリ)より得られた脱脂大
豆100gに1.5の水を加え、2N苛性ソーダ溶液
でPH7.6〜7.8に調整しつつ室温で1時間撹拌し蛋
白質成分を抽出する。次いで該抽出液を、ガーゼ
で濾過したのち、抽出液を18000r.p.m.で1時間
遠心分離し1.2の上清液を得た。得られた上清
液を濃氷酢酸でPH5.8とし、18000r.p.m.で1時間、
遠心分離して沈殿区分を除去し、上清液のPHを濃
氷酢酸で4.5とし、沈殿する区分を3000r.p.m.で20
分間、遠心分離して集め、該沈殿区分を500mlの
0.01M燐酸緩衝液(PH7.60)に溶解し、該緩衝液
(PH7.60)で十分透析する。得られた透析内液を
ダイヤフロー膜(米国、アミコン社製)で100ml
までで濃縮したのち0.01M燐酸緩衝液(PH7.60)
で緩衝化したバイオゲルP−100(米国、バイオラ
ド社製)を充填したカラム(5cm×90cm)にの
せ、上記緩衝液(PH7.60)で溶出し、15mlずつフ
ラクシヨンコレクターで分取し、No.66〜76に於い
て溶出する区分を集め、この区分をそのまま1cm
×20cmのDEAE−セフアデツクス(スウエーデ
ン、フアーマシヤ社製)のカラムに充填し、250
mlの容器を用いて塩化ナトリウムで0〜0.5Nま
での濃度勾配溶出を行ない、塩化ナトリウム濃度
0.23〜0.30Mに溶出する区分を集め、これを水に
透析後、凍結乾燥し、さらに上記カラムで再クロ
マトグラフイーを行なつて、本プロテアーゼ・イ
ンヒビター・の精製標品62.0mgを得た。[Table] The protease inhibitor of the present invention having the above-mentioned physicochemical properties can be used as a biochemical reagent.
It is also expected to have a wide range of uses as a medicine for treating acute pancreatitis and the like. Next, the protease inhibitor of the present invention
The manufacturing method will be described in detail. As the manufacturing raw materials used in the present invention, soybean varieties such as Bonminori, Yogetsu No. 1, Noki Shirahaka, and Kent from the United States are used, and soybeans of these varieties or soybeans are processed using conventional methods. The defatted soybeans that have been defatted by this process are either left as is or ground, and 10 to 20 times the volume of water or a salt solution such as sodium chloride or potassium chloride is added to the defatted soybeans, and the pH is adjusted with acetic acid, hydrochloric acid, sulfuric acid, phosphoric acid, etc.
Adjust to 5.4 to 5.8 and extract the protein while stirring if necessary. At this time, since the 11S component, which is one of the main protein components in soybeans, selectively precipitates at pH 5.4 to 5.8, the 11S component is removed by centrifugation. The resulting supernatant component was then PHed using the above-mentioned acid.
4.5 isoelectrically precipitated and then the supernatant soy whey fraction is separated by centrifugation. The obtained precipitated protein 0 is dissolved in 0.01M phosphate buffer (PH7.60), or the solution is placed in a dialysis membrane and dialyzed against the above buffer (PH7.60), and the dialyzed solution is subjected to diaflow. membrane (manufactured by Amicon, USA), collodion membrane (manufactured by West Germany,
Concentrate using a Sartorius membrane filter (manufactured by Sartorius Membrane Filter), etc. Next, the above solution or concentrate was added to Cephadex G-100 (manufactured by Pharmacia, Sweden).
Gel filtration using a column such as Biogel P-100 (manufactured by Bio-Rad, USA), or XM50,
Ultrafiltrate using a Diaflow ultrafiltration membrane such as XY100A (manufactured by Amicon, USA) to remove high molecular weight proteins such as 7S protein and collect only the 2S precipitate component. Next, the 2S precipitated components were treated with DEAE-Sephadex (manufactured by Pharmacia, Sweden) and DEAE-Cellulose (manufactured by Braun, USA).
After adsorption on an anion exchanger column such as
The protease inhibitor is obtained by elution using a difference in concentration of salts such as sodium chloride and potassium chloride, and by fractionation. In addition, when elution is performed using the above-mentioned sodium chloride based on a difference in salt concentration, the present protease inhibitor is eluted in the sodium chloride concentration range of 0.23 to 0.30 M (mol). Hereinafter, the present invention will be specifically explained with reference to Examples. Example 1 Soybeans (variety: Noki Shiruka) were crushed and heated at 38 to 40°C.
Add 1 water to 100 g of defatted soybean meal obtained by extraction with ethyl ether, adjust the pH to 5.8 with concentrated glacial acetic acid, and stir for 1 hour to extract protein components. Next, the extract was filtered through gauze to remove extraction residue, and the extract was centrifuged at 18,000 rpm for 1 hour.
680ml of supernatant liquid was obtained. Adjust the supernatant to pH4.5 with concentrated glacial acetic acid.
The precipitated protein fraction was collected by centrifugation at 3000 rpm for 10 minutes. Immediately suspend the obtained precipitate in 400 ml of 0.01M phosphate buffer (PH7.60),
Further, the mixture is dialyzed against the buffer solution (PH7.60) all day and night. Next, the dialyzed fluid was centrifuged at 30,000 rpm for 30 minutes.
After removing insoluble protein, this was placed in a 5 cm x 90
Pack 100 ml into a column of Sephadex G-100 (manufactured by Pharmacia, Sweden) of cm, perform gel filtration with the above buffer solution (PH 7.60), and collect 15 ml each with a fraction collector into Nos. 66 to 76. The eluted fraction was collected, thoroughly dialyzed against water, and then freeze-dried to obtain 320 mg of a sample. Next, 200 mg of the dried sample was dissolved in 0.01 M phosphate buffer (PH7.60), packed into a 1 cm x 20 cm column of DEAE-Sephadex (manufactured by Pharmacia, Sweden), and chlorinated using a 250 ml container. Perform concentration gradient elution with sodium from 0 to 0.5N, collect the fraction eluting at a sodium chloride concentration of 0.23 to 0.30M, dialyze it against water, freeze-dry it, and re-chromatograph it using the above column. Purified sample of this protease inhibitor 36.7
I got mg. Example 2 To 100 g of defatted soybeans obtained from soybeans (variety: Bonminori), 1.5 g of water was added, and while adjusting the pH to 7.6 to 7.8 with 2N caustic soda solution, the mixture was stirred at room temperature for 1 hour to extract protein components. Next, the extract was filtered through gauze, and then centrifuged at 18,000 rpm for 1 hour to obtain a supernatant of 1.2. The resulting supernatant was adjusted to pH 5.8 with concentrated glacial acetic acid and heated at 18000 rpm for 1 hour.
Centrifuge to remove the precipitated fraction, adjust the pH of the supernatant to 4.5 with concentrated glacial acetic acid, and centrifuge the precipitated fraction at 3000 rpm for 20 minutes.
Collect by centrifugation for 500 ml.
Dissolve in 0.01M phosphate buffer (PH7.60) and thoroughly dialyze against this buffer (PH7.60). 100 ml of the obtained dialysis solution was collected using a Diaflow membrane (manufactured by Amicon, USA).
After concentrating to 0.01M phosphate buffer (PH7.60)
Place it on a column (5 cm x 90 cm) packed with Biogel P-100 (manufactured by Bio-Rad, USA) buffered with No. Collect the eluting fraction between .66 and 76, and add this fraction to 1 cm.
Packed into a 20 cm DEAE column (manufactured by Pharmacia, Sweden),
Perform concentration gradient elution from 0 to 0.5N with sodium chloride using a ml container to determine the sodium chloride concentration.
The fraction eluting at 0.23-0.30M was collected, dialyzed against water, freeze-dried, and rechromatographed using the above column to obtain 62.0 mg of a purified sample of this protease inhibitor.
第1図は本発明のプロテアーゼ・インヒビタ
ー・のトリプシンに対する阻害活性の至適PH及
び安定PH範囲を示し、第2図は本プロテアーゼ・
インヒビター・のトリプシンに対する阻害活性
の作用適温の範囲を示し、又第3図は本プロテア
ーゼ・インヒビター・の電気泳動(デイスク電
気泳動法)を夫々示す図である。
Figure 1 shows the optimum pH and stable pH range of the inhibitory activity of the protease inhibitor of the present invention against trypsin, and Figure 2 shows the optimum pH and stable pH range of the protease inhibitor of the present invention.
The optimum temperature range for the inhibitory activity of the inhibitor against trypsin is shown, and FIG. 3 is a diagram showing the electrophoresis (disk electrophoresis method) of the present protease inhibitor.
Claims (1)
阻害物質−。 作用:トリプシンのみを阻害する。 至適PH及び安定PH範囲:いずれもPH3〜10で
ある。 作用適温の範囲:70℃以下。 分子量:28500。 等電点:PH4.65。 電気泳動:電気泳動的に均一である。 沈降定数及び拡散定数:沈降定数は2.68Sで
あり、拡散定数は9.21×10-7cm2/secである。 元素分析:C;42.35%、H;6.85%、N;
12.26%。 アミノ酸分析値:第2表の通り。[Claims] 1. A protease inhibitor having the following physical and chemical properties. Action: Inhibits trypsin only. Optimal PH and stable PH range: Both are PH3-10. Suitable temperature range for action: 70℃ or less. Molecular weight: 28500. Isoelectric point: PH4.65. Electrophoresis: Electrophoretically homogeneous. Sedimentation constant and diffusion constant: Sedimentation constant is 2.68S and diffusion constant is 9.21×10 −7 cm 2 /sec. Elemental analysis: C; 42.35%, H; 6.85%, N;
12.26%. Amino acid analysis value: As shown in Table 2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2669679A JPS55120519A (en) | 1979-03-09 | 1979-03-09 | Protease inhibiting substance-2 and its preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2669679A JPS55120519A (en) | 1979-03-09 | 1979-03-09 | Protease inhibiting substance-2 and its preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS55120519A JPS55120519A (en) | 1980-09-17 |
JPS6410520B2 true JPS6410520B2 (en) | 1989-02-22 |
Family
ID=12200545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2669679A Granted JPS55120519A (en) | 1979-03-09 | 1979-03-09 | Protease inhibiting substance-2 and its preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS55120519A (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5329909A (en) * | 1976-08-28 | 1978-03-20 | Kirin Brewery | Trypsin inhibitor and its preparation |
-
1979
- 1979-03-09 JP JP2669679A patent/JPS55120519A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS55120519A (en) | 1980-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sapolsky et al. | Metalloproteases of human articular cartilage that digest cartilage proteoglycan at neutral and acid pH. | |
CA1198697A (en) | Thrombolytic agent | |
Kajihara et al. | Crystalline Cytochrome b 5: I. Preparation of Crystalline Cytochrome b 5 from Rabbit Liver | |
Aronsson et al. | Characterization of glyoxalase I purified from pig erythrocytes by affinity chromatography | |
Taylor | Proteinases of the stomach in health and disease | |
JPS62174023A (en) | Anticoagulant substance, production thereof and anticoagulant agent containing said substance as active ingredient | |
WO1992003542A1 (en) | PROTEASES CAUSING ABNORMAL DEGRADATION OF AMYLOID β-PROTEIN PRECURSOR | |
Yano et al. | Partial purification and some properties of high molecular weight kininogen, bovine kininogen-I | |
US4500450A (en) | Polypeptide having an action on the immunological system, process for its isolation and purification, its use, agents containing this compound, and its cleavage products, their use and agents containing these products | |
Nathans et al. | Bovine milk xanthine oxidase. Purification by ultrafiltration and conventional methods which omit addition of proteases some criteria for homogeneity of native xanthine oxidase | |
Shkenderov | A protease inhibitor in bee venom Identification, Partial Purification and some Properties | |
Glaser et al. | Isolation and Characterization of Alpha-1-Antitrrpsin from the Cohn Fraction Iv-1 of Human Plasma | |
Miyahara et al. | On the Heterogeneity of Catalase from Goat Liver Purification and Characterization | |
CA1198672A (en) | Fibrinolytically active agent and a method for the preparation thereof | |
JÖNSSON et al. | Human granulocyte elastase is inhibited by the urinary trypsin inhibitor | |
Wilimowska-Pelc et al. | A simple method for isolating trypsin from trichloroacetic acid extracts of bovine pancreas | |
JPS6410520B2 (en) | ||
Delshammar et al. | Isolation and partial characterization of elastase from dog granulocytes. | |
CA1297634C (en) | Anticoagulating substance and preparation process thereof | |
JPS61162184A (en) | Novel fibrinolytic enzyme an production thereof | |
Baranowska et al. | Pyruvate kinase from human skeletal muscle | |
US5244807A (en) | Production of pseudomonas xa cells containing indolyl-3-alkane alpha-hydroxylase | |
JPS61171431A (en) | Amylase-inhibiting substance and preparation thereof | |
YAMAMOTO et al. | Separation and properties of three forms of cathepsin H-like cysteine proteinase from rat spleen | |
US3522229A (en) | Glycoprotein from saliva or salivary glands having gastric acid secretion inhibitory as well as anti-ulcerative activity and method of collecting the same |